Irodalom:
1. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y,
Voznyi E, Marabotti C, Van Cutsem E: V-325 Study Group.: Clinical benefit with docetaxel plus fluorouracil
and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or
gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007 Aug 1;25 (22):
3205-9.
2. Al-Batran SE, Atmaca A, Schleyer E, Pauligk C, Hosius C, Ehninger G, Jûger E: Imatinib mesylate for
targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin
in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer–a dose-escalation Phase I trial.
Cancer. 2007 May 1;109(9):1897-904.
3. Al-Batran SE, Kerber A, Atmaca A, Dechow C, Reitsamer E, Schmidt S, Kolassa Y, Neumann A, Weidmann
E, Hartmann JT, Jûger E: Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy
for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Onkologie.
2007 Feb;30(1-2):29-34. Epub 2007 Jan 26. Ann Surg Oncol. 2007 Jul;14(7):2028-35. Epub 2007 Apr 24.
4. Aurello P, D’Angelo F, Rossi S, Bellagamba R, Cicchini C, Nigri G, Ercolani G, De Angelis R,
Ramacciato G: Classification of lymph node metastases from gastric cancer: comparison between N-site and
N-number systems. Our experience and review of the literature. Am Surg. 2007 Apr;73(4):359-66. Review.
5. Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D’Argento E, Quirino M, Astone A, Cassano A:
Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.
Gastric Cancer. 2007;10(2):104-11. Epub 2007 Jun 25.
6. Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto
O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I: Italian Group for the Study of Digestive Tract
Cancer, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini
G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A:
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin,
cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst. 2007 Apr 18;99(8):601-7.
7. Cervantes A, Rodríguez Braun E, Pérez Fidalgo A, Chirivella González I: Molecular biology of gastric
cancer. Clin Transl Oncol. 2007 Apr;9(4):208-15. Review.
8. Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, Vaghi M, Aletti G, Caprotti R, Kaufman
H, Uggeri F: Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates
peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol. 2007 Apr;14(4):
1295-304. Epub 2007 Jan 17.
A gyomor 147
9. Chen G, Zhang FJ, Gong M, Yan M: Effect of perioperative autologous versus allogeneic blood transfusion
on the immune system in gastric cancer patients. J Zhejiang Univ Sci B. 2007 Aug;8(8):560-5.
10. Chen JH, Wu CW, Lo SS, Li AF, Hsieh MC, Shen KH, Lui WY: Outcome of distal gastric cancer with
pyloric stenosis after curative resection. Eur J Surg Oncol. 2007 Jun;33(5):556-60. Epub 2007 Feb 27.
11. Chiesa MD, Buti S, Tomasello G, Negri F, Buononato M, Brunelli A, Lazzarelli S, Brighenti M, Donati G,
Passalacqua R: A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and
irinotecan in metastatic gastric cancer. Tumori. 2007 May-Jun;93(3):244-7.
12. Cowell W, Summerhayes M: Pharmacoeconomic evaluation of capecitabine (Xeloda) for gastric cancer
in the United Kingdom. Pharmacoeconomics and Outcomes News 540 p. 7; 3 November, 2007
13. De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, Montemurro F, Cartenì G,
Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G: Gruppo Oncologico Italia
Meridionale. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen
in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale
(GOIM 9602 Study). Ann Oncol. 2007 Aug;18(8):1354-8. Epub 2007 May 24.
14. Dupont J, Jensen HA, Jensen BV, Pfeiffer P.: Phase I study of short-time oxaliplatin, capecitabine and
epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. Acta Oncol.
2007;46(3):330-5.
15. Enzinger PC, Benedetti JK, Meyerhardt JA, McCoy S, Hundahl SA, Macdonald JS, Fuchs CS.: Impact
of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007 Mar;245(3):426-34.
16. Fahlke J, Ridwelski K, Schmidt C, Hribaschek K, Stuebs P, Kettner E, Quietzsch D, Assmann M, Deist
T, Keilholz U, Lippert H.: A multicentre phase II study of docetaxel plus cisplatin for the treatment of
advanced gastric cancer. Chemotherapy. 2007;53(6):454-60. Epub 2007 Oct 23.
17. Farhat MH, Moumneh G, Jalloul R, El Hout Y.: Secondary adenocarcinoma of the urinary bladder from
a primary gastric cancer. J Med Liban. 2007 Jul-Sep;55(3):162-4. Review.
18. Findlay M, Storey D, Gebski V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A,
Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Truskett P, Goldstein D: AGITG. A
pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer:
Australasian Gastrointestinal Trials Group Study 9601. ANZ J Surg. 2007 Apr;77(4):247-52.
19. García-González MA, Lanas A, Quintero E, Nicolás D, Parra-Blanco A, Strunk M, Benito R, Angel Simón
M, Santolaria S, Sopeña F, Piazuelo E, Jiménez P, Pascual C, Mas E, Irún P, Espinel J, Campo R, Manzano M,
Geijo F, Pellisé M, González-Huix F, Nieto M, Espinós J, Titó L, Bujanda L, Zaballa M: Spanish
Gastroenterological Association AEG. Gastric cancer susceptibility is not linked to pro-and anti-in
flammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain. Am J
Gastroenterol. 2007 Sep;102(9):1878-92. Epub 2007 Jul 19.
20. Goral V, Yesilbagdan H, Kaplan A, Sit D.: Evaluation of CA 72-4 as a new tumor marker in patients
with gastric cancer. Hepatogastroenterology. 2007 Jun;54(76):1272-5.
21. Gretschel S, Bembenek A, Hünerbein M, Dresel S, Schneider W, Schlag PM.: Efficacy of different technical
procedures for sentinel lymph node biopsy in gastric cancer staging.
22. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, Jellum E, McColl KE.: Two distinct
aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter
pylori status. Gut. 2007 Jul;56(7):918-25. Epub 2007 Feb 22.
23. Hara T, Omura K, Hirano M, Asada Y, Munemoto Y, Sakamoto J.: A phase I study of paclitaxel, cisplatin,
and fluorouracil (TCF) for advanced gastric cancer. Cancer Chemother Pharmacol. 2007
Apr;59(5):631-6. Epub 2006 Aug 22.
24. Hou L, El-Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, Yeager M, Chanock SJ, Zatonski W,
148 Gastro Update 2008
Sobin LH, Lissowska J, Fraumeni JF Jr, Chow WH.: Polymorphisms in Th1-type cell-mediated
response genes and risk of gastric cancer. Carcinogenesis. 2007 Jan;28(1):118-23. Epub 2006 Aug 2.
25. Hua D, Huang ZH, Mao Y, Deng JZ.: Thymidylate synthase and thymidine phosphorylase gene expression
as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
World J Gastroenterol. 2007 Oct 7;13(37):5030-4.
26. Idelevich E, Karminsky N, Dinerman M, Katsenelson RL, Zvi NB, Baruch NB, Biran H, Man S, Shani
A.: Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in
metastatic gastric cancer. Acta Oncol. 2007;46(3):324-9.
27. Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M.: Postoperative chemoradiotherapy
in gastric cancer — a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and
capecitabine chemotherapy. Br J Cancer. 2007 Sep 17;97(6):712-6.
28. Jansen EP, Boot H, Saunders MP, Crosby TD, Dubbelman R, Bartelink H, Verheij M, Cats A.: A phase
I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol
Biol Phys. 2007 Dec 1;69(5):1424-8. Epub 2007 Aug 6.
29. Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC.:
Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic
and pharmacogenomic evaluations. Oncologist. 2007 May;12(5):543-54.
30. Jeung HC, Rha SY, Noh SH, Roh JK, Chung HC.:A phase II trial of weekly fractionated irinotecan and cisplatin
for advanced gastric cancer. Cancer Chemother Pharmacol. 2007 Feb;59(3):313-20. Epub 2006 Jun 13.
31. Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC.: A phase II study of S-1 monotherapy
administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance
status. Br J Cancer. 2007 Aug 20;97(4):458-63. Epub 2007 Jul 24.
32. Katsube T, Ogawa K, Ichikawa W, Fujii M, Tokunaga A, Takagi Y, Kochi M, Hayashi K, Kubota T, Aiba
K, Arai K, Terashima M, Kitajima M.: Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment
of advanced gastric cancer. Anticancer Drugs. 2007 Jun;18(5):605-10.
33. Kim JG, Sohn SK, Song HS, Kwon KY, Do YR, Lee KH, Hyun MS, Ryoo HM, Bae SH, Park KU, Baek
JH, Lee WS, Chung JS, Cho GJ, Sohn CH, Jang JS, Chung HY, Yu W.: Multicenter phase II study of
weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
Cancer Chemother Pharmacol. 2007 Nov;60(6):863-9. Epub 2007 Feb 27.
34. Kim JJ, Lee JH, Jung HY, Lee GH, Cho JY, Ryu CB, Chun HJ, Park JJ, Lee WS, Kim HS, Chung MG,
Moon JS, Choi SR, Song GA, Jeong HY, Jee SR, Seol SY, Yoon YB.: EMR for early gastric cancer in Korea:
a multicenter retrospective study. Gastrointest Endosc. 2007 Oct;66(4):693-700.
35. Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, Kim HJ.: A phase II study of irinotecan with bi-weekly,
low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage
therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol. 2007 Oct;37(10):744-
9. Epub 2007 Oct 8.
36. Kobayashi M, Oba K, Sakamoto J, Kondo K, Nagata N, Okabayashi T, Namikawa T, Hanazaki K.:
Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent
gastric cancer in Japan. Gastric Cancer. 2007;10(1):52-7. Epub 2007 Feb 23.
37. Kochi M, Fujii M, Kanamori N, Kaiga T, Aizaki K, Takahashi T, Takayama T.: Effect of gastrectomy on
the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. Cancer
Chemother Pharmacol. 2007 Oct;60(5):693-701. Epub 2007 Feb 15.
38. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T,
Ohashi N, Fujiwara M, Sakamoto J, Akimasa N; Chubu Clinical Cancer Group.: A phase II study of
weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer
Res. 2007 Jul-Aug;27(4C):2667-71.
A gyomor 149
39. Kolodziejczyk P, Pituch-Noworolska A, Drabik G, Kulig J, Szczepanik A, Sierzega M, Gurda A, opiela
T, Zembala M.: The effects of preoperative chemotherapy on isolated tumour cells in the blood and
bone marrow of gastric cancer patients. Br J Cancer. 2007 Sep 3;97(5):589-92. Epub 2007 Aug 14.
40. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A; Polish Gastric Cancer Study Group.:
Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis
of a multicenter, randomized, clinical trial. Am J Surg. 2007 Jan;193(1):10-5.
41. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT,
Ajani JA.: Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced
gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 1;109(1):33-40.
42. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C,
Lordick F.: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced
gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann
Oncol. 2007 Oct;18(10):1673-9. Epub 2007 Jul 28.
43. Lunet N, Valbuena C, Vieira AL, Lopes C, Lopes C, David L, Carneiro F, Barros H.: Fruit and vegetable
consumption and gastric cancer by location and histological type: case-control and meta-analysis. Eur J
Cancer Prev. 2007 Aug;16(4):312-27.
44. Lutz MP, Wilke H, Wagener DJ, Vanhoefer U, Jeziorski K, Hegewisch-Becker S, Balleisen L, Joossens E,
Jansen RL, Debois M, Bethe U, Praet M, Wils J, Van Cutsem E: European Organisation for Research
and Treatment of Cancer Gastrointestinal Group; Arbeitsgemeinschaft Internistische Onkologie. Weekly
infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus
biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation
for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische
Onkologie. J Clin Oncol. 2007 Jun 20;25(18):2580-5.
45. Makatsoris T, Papakostas P, Kalofonos HP, Xanthakis I, Tsavdaridis D, Aravantinos G, Gogas H, Klouvas G,
Kosmidis P, Pectasides D, Fountzilas G.: Intensive weekly chemotherapy with docetaxel, epirubicin and
carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative
Oncology Group (HeCOG) phase II study. Med Oncol. 2007;24(3):301-7.
46. Marchet A, Mocellin S, Ambrosi A, Morgagni P, Garcea D, Marrelli D, Roviello F, de Manzoni G, Minicozzi A,
Natalini G, De Santis F, Baiocchi L, Coniglio A, Nitti D: Italian Research Group for Gastric Cancer
(IRGGC). The ratio between metastatic and examined lymph nodes (N ratio) is an independent prog
nostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian
multicentric study in 1853 patients. Ann Surg. 2007 Apr;245(4):543-52.
47. Maruta F, Ishizone S, Hiraguri M, Fujimori Y, Shimizu F, Kumeda S, Miyagawa S.: A clinical study of
docetaxel with or without 5’DFUR as a second-line chemotherapy for advanced gastric cancer. Med
Oncol. 2007;24(1):71-5.
48. Mochiki E, Shioya M, Sakurai H, Andoh H, Ohno T, Aihara R, Asao T, Kuwano H.: Feasibility study of
postoperative intraperitoneal hyperthermochemotherapy by radiofrequency capacitive heating system
for advanced gastric cancer with peritoneal seeding. Int J Hyperthermia. 2007 Sep;23(6):493-500.
49. Mohri Y, Tonouchi H, Kobayashi M, Nakai K, Kusunoki M; Mie Surgical Infection Research Group:
Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer
surgery. Br J Surg. 2007 Jun;94(6):683-8.
50. Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, Ichinose M.: Serum pepsinogen and
gastric cancer screening. Intern Med. 2007;46(6):261-6. Epub 2007 Mar 15. Review.
51. Nagel G, Linseisen J, Boshuizen HC, Pera G, Del Giudice G, Westert GP, Bueno-de-Mesquita HB, Allen
NE, Key TJ, Numans ME, Peeters PH, Sieri S, Siman H, Berglund G, Hallmans G, Stenling R, Martinez C,
Arriola L, Barricarte A, Chirlaque MD, Quiros JR, Vineis P, Masala G, Palli D, Panico S, Tumino R,
Bingham S, Boeing H, Bergmann MM, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Olsen A,
150 Gastro Update 2008
Tjonneland A, Trichopoulou A, Bamia C, Soukara S, Sabourin JC, Carneiro F, Slimani N, Jenab M,
Norat T, Riboli E, González CA.: Socioeconomic position and the risk of gastric and oesophageal cancer
in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Epidemiol.
2007 Feb;36(1):66-76. Epub 2007 Jan 16.
52. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M,
Ohashi Y; on behalf of the National Surgical Adjuvant Study of Gastric Cancer Group.: Randomized
controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced
gastric cancer. Br J Surg. 2007 Dec;94(12):1468-76.
53. Neri B, Pantaleo P, Giommoni E, Grifoni R, Paoletti C, Rotella V, Pantalone D, Taddei A, Mercatelli A,
Tonelli P.: Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric
carcinoma: a phase II study. Br J Cancer. 2007 Apr 10;96(7):1043-6. Epub 2007 Mar 13.
54. Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, Kawamura S, Ando T,
Musha N, Konno H, Nagata N, Usuki H, Miyashita Y, Oba K, Morita S, Sakamoto J; Japanese South
West Oncology Group (JASWOG).: Multicenter phase II trial of combination chemotherapy with weekly
paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. J Chemother.
2007 Aug;19(4):444-50.
55. Nishikawa T, Maetani S.: Evaluation of intensive adjuvant chemotherapy in gastric cancer using life
expectancy compared with log-rank test as a measure of survival benefit. Ann Surg Oncol. 2007
Feb;14(2):348-54. Epub 2006 Nov 8.
56. Nomura S, Kaminishi M.: Surgical treatment of early gastric cancer. Dig Surg. 2007;24(2):96-100.
Epub 2007 Apr 25. Review.
57. Oh SC, Sur HY, Sung HJ, Choi IK, Park SS, Seo JH, Jeen YT, Chun HJ, Shin SW, Mok YJ, Kim JS, Kim YH.:
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients
with advanced or metastatic gastric cancer. Br J Cancer. 2007 May 21;96(10):1514-9. Epub 2007 May 1.
58. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ.: A phase II study of oxaliplatin with low dose
leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy
for patients with advanced gastric cancer. Acta Oncol. 2007;46(3):336-41.
59. Ozaki T, Tamura K, Satoh T, Kurata T, Shimizu T, Miyazaki M, Okamoto I, Nakagawa K, Fukuoka M.:
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. Anticancer
Res. 2007 Jul-Aug;27(4C):2657-65.
60. Palli D, Masala G, Del Giudice G, Plebani M, Basso D, Berti D, Numans ME, Ceroti M, Peeters PH,
Bueno de Mesquita HB, Buchner FL, Clavel-Chapelon F, Boutron-Ruault MC, Krogh V, Saieva C,
Vineis P, Panico S, Tumino R, Nyrén O, Simán H, Berglund G, Hallmans G, Sanchez MJ, Larrãnaga N,
Barricarte A, Navarro C, Quiros JR, Key T, Allen N, Bingham S, Khaw KT, Boeing H, Weikert C, Linseisen J,
Nagel G, Overvad K, Thomsen RW, Tjonneland A, Olsen A, Trichoupoulou A, Trichopoulos D, Arvaniti A,
Pera G, Kaaks R, Jenab M, Ferrari P, Nesi G, Carneiro F, Riboli E, Gonzalez CA.: CagA+ Helicobacter
pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer. 2007 Feb
15;120(4):859-67. Erratum in: Int J Cancer. 2007 Aug 15;121(4):928. E Numans, Mattijs
61. Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI.: Phase
II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer
Chemother Pharmacol. 2007 Jan;59(1):17-21. Epub 2006 May 24.
62. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M,
Francini G.: Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer:
a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008
Jan;61(1):105-11. Epub 2007 Apr 12.
63. Rosati G, Bilancia D, Germano D, Dinota A, Romano R, Reggiardo G, Manzione L.: Reduced dose
intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with
A gyomor 151
metastatic gastric cancer: a phase II study. Ann Oncol. 2007 Jun;18 Suppl 6:vi128-32.
64. Rosero-Bixby L, Sierra R.: X-ray screening seems to reduce gastric cancer mortality by half in a communitycontrolled
trial in Costa Rica. Br J Cancer. 2007 Oct 8;97(7):837-43. Epub 2007 Oct 2.
65. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R,
Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer
Research.: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and
fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the
Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23.
66. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R,
Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F: Swiss Group for Clinical Cancer
Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and
fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the
Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23.
67. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T,
Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group.: Adjuvant
chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov
1;357(18):1810-20.
68. Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishihara Y, Yamada A,
Tanaka N, Itoh K, Harada M, Todo S.: Immunological evaluation of personalized peptide vaccination
in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma
patients. Cancer Sci. 2007 Jul;98(7):1113-9. Epub 2007 Apr 23.
69. Seno H, Satoh K, Tsuji S, Shiratsuchi T, Harada Y, Hamajima N, Sugano K, Kawano S, Chiba T.: Novel
interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric
cancer in Japan: comprehensive analysis of 207 polymorphisms of 11 cytokine genes. J Gastroenterol
Hepatol. 2007 May;22(5):729-37.
70. Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, Yoo NC, Roh JK, Chung HC.: Capecitabine and
doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer
Chemother Pharmacol. 2008 Jan;61(1):157-65. Epub 2007 Apr 11.
71. Skarlos DV, Bai M, Goussia A, Samantas E, Galani E, Tsavdaridis D, Karina M, Papakostas P, Konstantara A,
Fountzilas G.: Expression of a molecular marker panel as a prognostic tool in gastric cancer patients
treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology
Group. Anticancer Res. 2007 Jul-Aug;27(4C):2973-83.
72. Takayama T, Sato Y, Sagawa T, Okamoto T, Nagashima H, Takahashi Y, Ohnuma H, Kuroiwa G, Miyanishi K,
Takimoto R, Matsunaga T, Kato J, Yamaguchi K, Hirata K, Niitsu Y.: Phase I study of S-1, docetaxel
and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J
Cancer. 2007 Oct 8;97(7):851-6. Epub 2007 Sep 11.
73. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K.: Baseline gastric mucosal atrophy
is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication
therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007 Jan;42 Suppl 17:21-7.
74. Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, Miyoshi M, Yumoto E, Imagawa A,
Toyokawa T, Sakaguchi K, Shiratori Y.: Helicobacter pylori eradication reduced the incidence of gastric
cancer, especially of the intestinal type. Aliment Pharmacol Ther. 2007 Apr 1;25(7):805-12.
75. Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, Wong LC, Leong CN, Zhu M.: The role
of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol
Phys. 2007 Feb 1;67(2):385-8. Epub 2006 Nov 21.
76. Thompson AM, Rapson T, Gilbert FJ, Park KG: Scottish Audit of Gastric and Oesophageal Cancer.
152 Gastro Update 2008
Hospital volume does not influence long-term survival of patients undergoing surgery for oesophageal
or gastric cancer. Br J Surg. 2007 May;94(5):578-84.
77. Tsujinaka T, Sasako M, Yamamoto S, Sano T, Kurokawa Y, Nashimoto A, Kurita A, Katai H, Shimizu T,
Furukawa H, Inoue S, Hiratsuka M, Kinoshita T, Arai K, Yamamura Y: Gastric Cancer Surgery Study
Group of Japan Clinical Oncology Group. Influence of overweight on surgical complications for gastric
cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy
(JCOG9501). Ann Surg Oncol. 2007 Feb;14(2):355-61. Epub 2006 Dec 5.
78. Uedo N, Takeuchi Y, Yamada T, Ishihara R, Ogiyama H, Yamamoto S, Kato M, Tatsumi K, Masuda E,
Tamai C, Yamamoto S, Higashino K, Iishi H, Tatsuta M.: Effect of a proton pump inhibitor or an H2-
receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of
early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol. 2007
Aug;102(8):1610-6. Epub 2007 Mar 31.
79. Wang C, Yuan Y, Hunt RH.: The association between Helicobacter pylori infection and early gastric cancer:
a meta-analysis. Am J Gastroenterol. 2007 Aug;102(8):1789-98. Epub 2007 May 23.
80. Welz S, Hehr T, Kollmannsberger C, Bokemeyer C, Belka C, Budach W.: Renal toxicity of adjuvant
chemoradiotherapy with cisplatin in gastric cancer. Int J Radiat Oncol Biol Phys. 2007 Dec
1;69(5):1429-35. Epub 2007 Aug 9.
81. Wydmanski J, Suwinski R, Poltorak S, Maka B, Miszczyk L, Wolny E, Bielaczyc G, Zajusz A.: The tolerance
and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a
phase II study. Radiother Oncol. 2007 Feb;82(2):132-6. Epub 2007 Feb 6.
82. Yamaguchi K, Nakagawa S, Yabusaki H, Nashimoto A.: Combination chemotherapy with 5-fluorouracil,
cisplatin and paclitaxel for pretreated patients with advanced gastric cancer. Anticancer Res. 2007 SepOct;27(5B):3535-9.
83. Yeo W, Boyer M, Chung HC, Ong SY, Lim R, Zee B, Ma B, Lam KC, Mo FK, Ng EK, Ho R, Clarke S,
Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan AT; Cancer Therapeutics Research Group
(CTRG).: Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter
study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemother Pharmacol. 2007
Feb;59(3):295-300. Epub 2006 Jun 17.
84. Yonemura Y, Bando E, Kawamura T, Ito H, Endo Y, Miura M, Kiyosaki K, Sasaki T.: Cytoreduction and
intraperitoneal chemotherapy for carcinomatosis from gastric cancer. Cancer Treat Res. 2007;134:357-73.
Review.
85. Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, Kamata S, Yamamoto H, Kim BS,
Matsuki N, Sawa T, Noh SH; East Asia Surgical Oncology Group.: Metastasis in para-aortic lymph
nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy.
Hepatogastroenterology. 2007 Mar;54(74):634-8.
86. Zhang CX, Huang S, Xu N, Fang JW, Shen P, Bao YH, Mou BH, Shi MG, Zhong XL, Xiong PJ.: Phase
II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in
patients with metastatic or advanced gastric cancer. Anticancer Drugs. 2007 Jun;18(5):581-6.
87. Zhou Y, Ran J, Tang C, Wu J, Honghua L, Xingwen L, Ning C, Qiao L.: Effect of celecoxib on E-cadherin,
VEGF, Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther. 2007 Feb;6(2):269-75.
Epub 2007 Feb 26.
